Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage company developing therapeutics for genetically driven neuromuscular diseases, has announced its upcoming participation in the Stifel 2025 Virtual CNS Forum. The company's management will engage in a fireside chat scheduled for Tuesday, March 18, 2025 at 4:00 p.m. ET.
Investors and interested parties can access the live webcast through the Investors & Media section of Dyne's website. The presentation recording will remain available for replay on the company's platform for 90 days following the event.
Dyne Therapeutics (Nasdaq: DYN), un'azienda in fase clinica che sviluppa terapie per malattie neuromuscolari di origine genetica, ha annunciato la sua prossima partecipazione al Stifel 2025 Virtual CNS Forum. La direzione dell'azienda parteciperà a una chiacchierata informale programmata per martedì 18 marzo 2025 alle 16:00 ET.
Gli investitori e le parti interessate possono accedere alla diretta tramite la sezione Investitori & Media del sito web di Dyne. La registrazione della presentazione rimarrà disponibile per la visione on-demand sulla piattaforma dell'azienda per 90 giorni dopo l'evento.
Dyne Therapeutics (Nasdaq: DYN), una empresa en etapa clínica que desarrolla terapias para enfermedades neuromusculares de origen genético, ha anunciado su próxima participación en el Stifel 2025 Virtual CNS Forum. La dirección de la empresa participará en una charla informal programada para martes, 18 de marzo de 2025 a las 4:00 p.m. ET.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores y Medios del sitio web de Dyne. La grabación de la presentación estará disponible para su reproducción en la plataforma de la empresa durante 90 días después del evento.
Dyne Therapeutics (Nasdaq: DYN), 유전적으로 유발되는 신경근육 질환 치료제를 개발하는 임상 단계 회사가 Stifel 2025 Virtual CNS Forum에 참가할 예정이라고 발표했습니다. 회사 경영진은 2025년 3월 18일 화요일 오후 4시(ET)에 예정된 파이어사이드 채팅에 참여할 것입니다.
투자자와 관심 있는 분들은 Dyne 웹사이트의 투자자 및 미디어 섹션을 통해 생중계에 접근할 수 있습니다. 발표 녹화는 이벤트 후 90일 동안 회사 플랫폼에서 다시 볼 수 있습니다.
Dyne Therapeutics (Nasdaq: DYN), une entreprise en phase clinique développant des thérapies pour des maladies neuromusculaires d'origine génétique, a annoncé sa prochaine participation au Stifel 2025 Virtual CNS Forum. La direction de l'entreprise participera à une discussion informelle prévue pour mardi 18 mars 2025 à 16h00 ET.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section Investisseurs & Médias du site Web de Dyne. L'enregistrement de la présentation restera disponible en rediffusion sur la plateforme de l'entreprise pendant 90 jours après l'événement.
Dyne Therapeutics (Nasdaq: DYN), ein Unternehmen in der klinischen Phase, das Therapien für genetisch bedingte neuromuskuläre Erkrankungen entwickelt, hat seine bevorstehende Teilnahme am Stifel 2025 Virtual CNS Forum bekannt gegeben. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 18. März 2025 um 16:00 Uhr ET geplant ist.
Investoren und Interessierte können über den Bereich Investoren & Medien auf der Website von Dyne auf den Live-Stream zugreifen. Die Aufzeichnung der Präsentation wird 90 Tage nach der Veranstaltung auf der Plattform des Unternehmens verfügbar sein.
- None.
- None.
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 4:00 p.m. ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
About Dyne Therapeutics
Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
Dyne Therapeutics
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
Dyne Therapeutics
snartker@dyne-tx.com
781-317-1938
FAQ
When is Dyne Therapeutics (DYN) presenting at the Stifel 2025 Virtual CNS Forum?
How can investors watch Dyne Therapeutics' (DYN) Stifel CNS Forum presentation?
How long will Dyne Therapeutics' (DYN) Stifel presentation replay be available?
What is the focus area of Dyne Therapeutics (DYN)?
